Clarity Pharmaceuticals (ASX:CU6) signed a copper-64 isotope supply agreement with the University of Queensland's Australian Institute for Biotechnology and Nanotechnology, according to a Wednesday Australian bourse filing.
The supply agreement will support the firm's clinical trials with copper-64 SAR-bisPSMA imaging agent in Australia for prostate cancer patients. It will also support the rollout of two theranostic preclinical programs, SAR-bisFAP and SAR-trastuzumab.
It will expand the manufacturing capability of the agent for the phase three CLARIFY and AMPLIFY registrational trials in Australia, an ongoing investigator-initiated trial, as well as the Co-PSMA and SECuRE theranostic trials.
The firm's shares rose 2% in recent trading on Wednesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。